ANSWER: C

Rationale:

This question asked you to identify the mechanism underlying incomplete recovery from drug-induced parkinsonism in older patients. Option C is correct. Drug-induced parkinsonism can unmask subclinical idiopathic Parkinson's disease in susceptible individuals — particularly older patients who may already have reduced dopaminergic reserve from early, pre-symptomatic neurodegeneration. In these patients, the pharmacological D2 blockade tips a pre-existing but compensated dopaminergic deficit into overt clinical parkinsonism. When the causative drug is withdrawn, the pharmacological blockade resolves, but the underlying neurodegenerative process continues. The residual parkinsonism after drug withdrawal is therefore not a failure of receptor recovery but evidence of idiopathic PD that was present all along. This is clinically important: incomplete recovery after drug withdrawal should prompt evaluation for underlying PD rather than assumption of drug effect persistence.

• Option A: Option A is incorrect. While older patients do have reduced renal clearance and metoclopramide elimination may be prolonged, this pharmacokinetic effect does not account for incomplete recovery months after discontinuation, when the drug would be expected to have been fully cleared regardless of renal function.
• Option B: Option B is incorrect. Metoclopramide does not permanently downregulate D2 receptors; D2 receptor blockade by competitive antagonists is reversible, and receptor density normalizes after drug clearance.
• Option D: Option D is incorrect. D2 receptor blockade does not cause direct neuronal damage to dopaminergic neurons; DIP results from pharmacological receptor occupancy, not neurotoxicity, and hepatic regenerative capacity is not relevant to receptor recovery.
• Option E: Option E is incorrect. Metoclopramide is a competitive, reversible D2 receptor antagonist; it does not produce irreversible conformational changes in the D2 receptor, and receptor function fully normalizes once the drug is eliminated.

ANSWER: A

Rationale:

This question asked you to identify the precise mechanism by which carbidopa improves levodopa therapy. Option A is correct. Aromatic amino acid decarboxylase (AADC), also called DOPA decarboxylase, is the enzyme responsible for converting levodopa to dopamine. When levodopa is given without an AADC inhibitor, approximately 95% of each oral dose is converted to dopamine in the peripheral tissues — the gut wall, liver, and peripheral vasculature — before reaching the brain. Peripheral dopamine cannot cross the blood-brain barrier and instead causes dose-limiting nausea, vomiting, and cardiovascular effects. Carbidopa inhibits peripheral AADC without crossing the blood-brain barrier itself, blocking this peripheral conversion and allowing a much larger fraction of each levodopa dose to reach the CNS. This substantially reduces the required levodopa dose and the severity of peripheral adverse effects.

• Option B: Option B is incorrect. Carbidopa does not inhibit COMT; COMT inhibition is the mechanism of entacapone and tolcapone, which are a separate class of adjunct agents added to levodopa/carbidopa to further extend levodopa bioavailability.
• Option C: Option C is incorrect. Carbidopa does not interact with the large neutral amino acid transporter; it acts intracellularly as an AADC inhibitor and has no activity at membrane transport proteins.
• Option D: Option D is incorrect. Carbidopa does not inhibit MAO-B; MAO-B inhibition is the mechanism of selegiline and rasagiline, which are used as adjunct antiparkinson agents and as potential neuroprotective treatments.
• Option E: Option E is incorrect. Carbidopa does not compete with amino acids for intestinal absorption sites and has no meaningful effect on levodopa intestinal uptake; its action is post-absorption, at the enzymatic level, preventing peripheral AADC-mediated conversion.

ANSWER: D

Rationale:

This question asked you to identify the pharmacokinetic mechanism underlying the ciprofloxacin-rasagiline drug interaction. Option D is correct. Rasagiline is metabolized primarily by the hepatic cytochrome P450 enzyme CYP1A2 through N-dealkylation to its principal metabolite, aminoindan. Ciprofloxacin is a potent inhibitor of CYP1A2. When ciprofloxacin inhibits CYP1A2-mediated rasagiline metabolism, rasagiline clearance is substantially reduced, plasma concentrations rise, and the risk of MAO-B inhibitor-related adverse effects — including hypertensive reactions and serotonergic interactions with co-administered drugs — increases. This interaction is clinically documented and is flagged in rasagiline prescribing information; ciprofloxacin should be used with caution in patients on rasagiline, and alternative antibiotics without CYP1A2 inhibitory activity should be considered where feasible.

• Option A: Option A is incorrect. P-glycoprotein efflux inhibition affects CNS drug distribution but does not significantly alter rasagiline systemic plasma concentrations; this is not the primary mechanism of the interaction.
• Option B: Option B is incorrect. Rasagiline is not significantly eliminated by renal tubular secretion; its primary route of elimination is hepatic metabolism via CYP1A2, and renal competition is not the basis for this interaction.
• Option C: Option C is incorrect. CYP1A2 is the metabolizing enzyme for rasagiline, and ciprofloxacin inhibits rather than induces it; additionally, rasagiline is not a prodrug requiring activation — it is pharmacologically active as administered.
• Option E: Option E is incorrect. Rasagiline has limited plasma protein binding relative to many CNS drugs, and ciprofloxacin does not produce clinically meaningful displacement of rasagiline from protein binding sites; displacement interactions of this type are generally not significant at clinical concentrations.

ANSWER: B

Rationale:

This question asked you to identify the syndrome produced by abrupt dopamine agonist discontinuation. Option B is correct. Dopamine agonist withdrawal syndrome is a recognized and distinct clinical entity characterized by a constellation of non-motor symptoms — severe anxiety, panic attacks, dysphoria, diaphoresis, pain, fatigue, and drug craving — that emerge when dopamine agonists are abruptly discontinued or rapidly reduced after chronic use. The syndrome is thought to reflect the dependence of mesolimbic reward circuitry on chronic dopaminergic agonist stimulation; abrupt removal produces a withdrawal state analogous in some respects to substance withdrawal. Motor symptoms also worsen with the loss of dopaminergic support. Management requires slow tapering rather than abrupt cessation. Patients should be explicitly warned not to stop dopamine agonists suddenly.

• Option A: Option A is incorrect. Neuroleptic malignant syndrome is caused by acute dopaminergic deficiency from antipsychotic D2 receptor blockade and is characterized by hyperthermia, severe rigidity, autonomic instability, and altered consciousness — a very different and more severe clinical picture than dopamine agonist withdrawal syndrome.
• Option C: Option C is incorrect. Pramipexole does not competitively occupy levodopa receptors in a way that causes toxicity upon its removal; the symptoms described here are withdrawal symptoms, not levodopa excess, and levodopa toxicity would present with dyskinesia, nausea, and psychosis rather than dysphoria and drug craving.
• Option D: Option D is incorrect. While some non-ergot dopamine agonists do have activity at 5-HT1A receptors, serotonin discontinuation syndrome is not the established mechanism for the symptoms that follow dopamine agonist withdrawal; the clinical picture is pharmacologically attributed to mesolimbic dopaminergic dependence.
• Option E: Option E is incorrect. Rebound cholinergic excess is not the mechanism of dopamine agonist withdrawal syndrome; the syndrome reflects mesolimbic dopamine dependence, not a change in the cholinergic-dopaminergic balance in the striatum.

ANSWER: E

Rationale:

This question asked you to identify the primary life-threatening complication of prolonged levodopa withdrawal in a postoperative patient with advanced Parkinson's disease. Option E is correct. Levodopa has a plasma half-life of approximately one hour. When levodopa is withheld for extended periods, the dopaminergic support for motor function rapidly collapses. In a patient with advanced PD who is heavily dependent on medication for any functional motor activity, this produces acute akinesia — a state of near-complete motor arrest — along with severe rigidity. Dysphagia becomes profound as the muscles of swallowing lose dopaminergic support, creating an immediate and life-threatening aspiration risk. Aspiration pneumonia is a leading cause of death in advanced PD, and the perioperative period is a recognized high-risk window. Restarting antiparkinson medications at the earliest safe postoperative opportunity is a clinical imperative, and the surgical team must be explicitly informed that holding levodopa carries this specific risk.

• Option A: Option A is incorrect. Dopamine receptor supersensitivity causing dyskinesia is a phenomenon associated with levodopa re-introduction after a period of withdrawal, not with the withdrawal itself; the acute withdrawal state produces hypokinesia, not hyperkinesia.
• Option B: Option B is incorrect. Levodopa withdrawal does not cause hypertensive crisis from peripheral catecholamine release; this mechanism is not established for levodopa discontinuation, and peripheral dopamine levels actually fall when levodopa is withdrawn.
• Option C: Option C is incorrect. While a neuroleptic malignant-like syndrome has been reported with acute dopaminergic withdrawal in PD, particularly when many medications are stopped simultaneously, the most direct and common acute complication in the postoperative NPO context is akinesia with aspiration risk — the clinical picture described in this question — rather than the full NMS syndrome with hyperthermia and rhabdomyolysis.
• Option D: Option D is incorrect. Acute psychosis from rebound mesolimbic dopamine activity is not a recognized consequence of levodopa withdrawal; levodopa withdrawal reduces rather than increases dopamine availability throughout the brain, making rebound mesolimbic excess pharmacologically implausible.

ANSWER: C

Rationale:

This question asked you to identify which dopamine agonist has the greatest human pregnancy experience and what distinguishes its safety profile. Option C is correct. Bromocriptine is an ergot-derived dopamine agonist that accumulated substantial human pregnancy exposure data long before it was used for Parkinson's disease, primarily through its established use in treating hyperprolactinemia, galactorrhea, and dopamine agonist-responsive infertility. This historical use in women of reproductive age means that more human pregnancy outcome data exists for bromocriptine than for the non-ergot agonists pramipexole, ropinirole, and rotigotine, which are predominantly used in older PD populations and have limited pregnancy databases. Despite not being clearly teratogenic, bromocriptine carries a concern for uterine contractility — ergot compounds can stimulate uterine smooth muscle, raising the theoretical risk of preterm labor or uterine hyperstimulation.

• Option A: Option A is incorrect. Pramipexole does not have the most human pregnancy data; as a non-ergot agonist used predominantly in older PD patients, its pregnancy database is limited to case reports. Neonatal dopaminergic withdrawal syndrome is not an established specific concern in the same way uterine contractility is for bromocriptine.
• Option B: Option B is incorrect. While ropinirole has been used in some cases of restless legs syndrome in pregnancy, its pregnancy database is limited and it does not have the most pregnancy data among the dopamine agonists; fetal cardiac arrhythmia is not its established primary pregnancy concern.
• Option D: Option D is incorrect. Rotigotine's transdermal delivery does not confer particular pregnancy safety advantages, and it does not have the most pregnancy data; local teratogenicity from a transdermal formulation is not a recognized concern.
• Option E: Option E is incorrect. Cabergoline, like bromocriptine, has pregnancy data from prolactinoma treatment, but bromocriptine has the longer track record and larger historical dataset; neonatal extrapyramidal symptoms from dopamine agonist exposure are not the established primary concern for cabergoline in pregnancy.

ANSWER: A

Rationale:

This question asked you to identify which anesthetic agent requires specific caution in the dopaminergic context of treated Parkinson's disease and explain the mechanism. Option A is correct. Ketamine exerts sympathomimetic effects by stimulating catecholamine release from sympathetic nerve terminals and the adrenal medulla, producing tachycardia, hypertension, and increased cardiac output. In a patient with Parkinson's disease on dopaminergic therapy — where central and peripheral catecholaminergic tone is already elevated or sensitized — these sympathomimetic effects can be amplified, increasing the risk of hemodynamic instability. The combination of ketamine's catecholamine-releasing properties with the sensitized cardiovascular state in levodopa-treated patients requires careful monitoring. Regional anesthesia is generally preferred in PD when surgically feasible specifically to avoid this and other interaction landscapes of inhaled and intravenous anesthetic agents.

• Option B: Option B is incorrect. Propofol does not inhibit AADC activity in the brain; it is generally considered an acceptable anesthetic agent in PD patients without specific contraindications, and there is no established mechanism by which propofol precipitates acute akinesia through dopamine synthesis inhibition.
• Option C: Option C is incorrect. Isoflurane does not block striatal D2 receptors; volatile anesthetic agents modulate GABA receptors and NMDA receptors, not dopamine receptors, and isoflurane is generally considered acceptable in PD patients without specific dopaminergic contraindications.
• Option D: Option D is incorrect. While benzodiazepines do enhance GABAergic inhibition, midazolam does not specifically inhibit dopaminergic neurons in the substantia nigra in a way that produces clinically significant acute motor deterioration; benzodiazepines are not specifically contraindicated in PD for this reason, though they carry sedation and fall risk concerns in older patients.
• Option E: Option E is incorrect. Succinylcholine-induced fasciculations do not trigger massive dopamine release from nigrostriatal terminals, and succinylcholine does not have a specific contraindication in PD related to dopaminergic mechanisms; standard neuromuscular monitoring and reversal precautions apply to all PD patients due to baseline respiratory compromise, not because of dopamine-specific interactions.

ANSWER: D

Rationale:

This question asked you to identify the mechanism by which a proton pump inhibitor reduces levodopa bioavailability. Option D is correct. Levodopa dissolution and absorption depend in part on the acidic gastric environment. Levodopa tablets must dissolve in the stomach before the drug can be presented to the absorptive surface of the upper small intestine. Proton pump inhibitors (PPIs) such as omeprazole suppress gastric acid secretion and raise gastric pH toward neutral. This reduced acidity impairs tablet dissolution kinetics, slows the rate at which levodopa is delivered in solution to the small intestine, and can reduce the extent of absorption — particularly for immediate-release formulations. The clinical consequence in a patient with an already-narrow therapeutic window is wearing-off and reduced peak motor effect. PPIs are frequently overlooked as a source of levodopa variability and should be part of the medication reconciliation review in any PD patient with unexplained motor deterioration.

• Option A: Option A is incorrect. Levodopa is not significantly metabolized by CYP1A2; its primary metabolic pathways are AADC-mediated conversion to dopamine and COMT-mediated O-methylation. Omeprazole has variable CYP interactions but this mechanism is not the basis for reduced levodopa efficacy.
• Option B: Option B is incorrect. Omeprazole does not chelate levodopa to form an insoluble complex; chelation interactions of this type are characteristic of agents such as calcium, iron, and antacid cations, not proton pump inhibitors.
• Option C: Option C is incorrect. Omeprazole does not induce intestinal P-glycoprotein to a degree that would meaningfully reduce levodopa absorption; levodopa is not a significant P-glycoprotein substrate, and this is not a recognized mechanism for the PPI-levodopa interaction.
• Option E: Option E is incorrect. Omeprazole does not inhibit the large neutral amino acid transporter; this transporter is responsible for levodopa intestinal absorption, but its inhibition by dietary amino acids — not by omeprazole — is the relevant competitive mechanism for meal-related levodopa variability.

ANSWER: B

Rationale:

This question asked you to identify the age-related physiological change most responsible for increased levodopa pharmacokinetic variability in older adults. Option B is correct. Gastric emptying rate is a major determinant of levodopa absorption kinetics. Levodopa is absorbed almost exclusively in the proximal small intestine, and the rate at which it is delivered from the stomach to the duodenum governs the timing and shape of the plasma concentration curve. Gastric emptying slows with advancing age due to reduced motility, and this slowing is also variable — differing not only between patients but between doses in the same patient depending on posture, meal composition, autonomic function, and intercurrent illness. This variability in gastric delivery translates directly into variable plasma peak concentrations, variable timing of peak effect, and exaggerated wearing-off periods, even with consistent dosing. This is a recognized pharmacokinetic challenge in older PD patients that is clinically distinct from the wearing-off that occurs from disease progression.

• Option A: Option A is incorrect. Blood-brain barrier permeability does not decrease significantly with normal aging in a way that would produce dose-to-dose variability in levodopa CNS penetration; age-related changes in LNAA transporter function are more relevant than permeability changes, and they are a relatively stable rather than dose-variable factor.
• Option C: Option C is incorrect. Levodopa does not undergo significant hepatic CYP enzyme-mediated first-pass metabolism; its primary metabolic pathways are AADC-mediated conversion and COMT-mediated O-methylation, neither of which is primarily CYP-dependent or subject to variable CYP aging effects.
• Option D: Option D is incorrect. While age-related changes in blood-brain barrier transport do occur, reductions in LNAA transporter density are not established as a primary source of dose-to-dose variability in levodopa CNS uptake; dietary protein competition at the transporter is a much more clinically relevant variable.
• Option E: Option E is incorrect. Peripheral AADC activity in the gut wall is substantially inhibited by carbidopa given concurrently with levodopa; age-related changes in peripheral AADC activity are not a recognized cause of dose-to-dose levodopa variability in patients receiving standard levodopa/carbidopa therapy.

ANSWER: E

Rationale:

This question asked you to correctly characterize the use of propofol and isoflurane in Parkinson's disease. Option E is correct. Propofol, an intravenous anesthetic that acts primarily through potentiation of GABA-A receptors, is generally considered acceptable for use in PD patients without specific contraindications related to dopaminergic mechanisms. Similarly, isoflurane, a volatile halogenated anesthetic agent, is generally acceptable in PD. Neither agent carries a specific dopaminergic contraindication comparable to the sympathomimetic concern with ketamine or the catecholamine sensitization historically associated with halothane. The preferred anesthetic strategy in PD patients overall is regional anesthesia when surgically feasible — not because propofol or isoflurane are specifically dangerous, but because regional anesthesia avoids the entire interaction landscape of general anesthetic agents and reduces the risk of postoperative delirium. When general anesthesia is required, propofol induction and isoflurane maintenance are standard and acceptable approaches.

• Option A: Option A is incorrect. Neither propofol nor isoflurane inhibits dopamine synthesis in the substantia nigra; they do not interact with the dopamine biosynthetic pathway, and this is not a basis for contraindication in PD.
• Option B: Option B is incorrect. Propofol does not block D2 receptors; it is a GABA-A potentiating agent with no significant dopamine receptor affinity, and it is not contraindicated in PD on this basis.
• Option C: Option C is incorrect. Isoflurane is not associated with the catecholamine-sensitizing cardiac arrhythmia risk that was characteristic of halothane; this distinction is important because halothane is now rarely used, and isoflurane and other modern volatile agents do not share this specific property to a clinically significant degree.
• Option D: Option D is incorrect. Ketamine is the agent that requires particular caution in PD due to its sympathomimetic catecholamine-releasing properties; recommending ketamine as the primary agent in PD specifically inverts the risk profile.

ANSWER: D

Rationale:

This question asked you to identify the expected DAT scan result in valproic acid-induced parkinsonism and interpret its mechanistic significance. Option D is correct. The dopamine transporter (DAT) is expressed on the presynaptic terminals of nigrostriatal dopaminergic neurons. DAT binding on SPECT imaging reflects the structural integrity of these presynaptic terminals — it is reduced only when terminals are lost through neurodegeneration, as in idiopathic Parkinson's disease. In valproic acid-induced parkinsonism, the prevailing mechanism involves mitochondrial dysfunction in dopaminergic neurons, which impairs their function without causing the structural terminal loss that would reduce DAT binding. The nigrostriatal neurons are dysfunctional but structurally present, and DAT binding is therefore normal. A normal DAT scan in a patient with clinical parkinsonism is a strong signal pointing away from idiopathic PD and toward a drug-induced or functional cause. If valproic acid is the cause, improvement should follow dose reduction or discontinuation — though recovery may be incomplete in older patients if subclinical PD was unmasked.

• Option A: Option A is incorrect. Reduced bilateral DAT binding indicates structural loss of presynaptic dopaminergic terminals, which is the hallmark of idiopathic PD and atypical parkinsonisms with nigrostriatal degeneration; valproic acid does not cause this structural terminal loss at therapeutic doses.
• Option B: Option B is incorrect. Asymmetric DAT reduction is characteristic of early idiopathic PD, which begins with unilateral or asymmetric nigrostriatal degeneration; drug-induced parkinsonism produces a normal DAT scan, not an asymmetric one.
• Option C: Option C is incorrect. Caudate-selective DAT reduction is associated with certain atypical parkinsonian syndromes but is not the expected pattern in drug-induced parkinsonism from valproic acid, which produces a normal scan.
• Option E: Option E is incorrect. Globally reduced DAT binding is not the expected finding in valproic acid-induced parkinsonism; the normal DAT scan is the discriminating result, and a globally reduced scan would imply structural terminal loss rather than functional impairment.

ANSWER: C

Rationale:

This question asked you to precisely characterize the protein redistribution dietary strategy for meal-related levodopa wearing-off. Option C is correct. The protein redistribution diet concentrates most of the day's protein intake in the evening meal, when the need for reliable motor function and levodopa efficacy is typically less critical — evening activities, including sleep, impose fewer motor demands than daytime work, driving, or social engagement. Keeping breakfast and lunch low in protein minimizes the large neutral amino acid (LNAA) load competing with levodopa at the intestinal transporter and at the blood-brain barrier during the active daytime period. This strategy improves the consistency and peak magnitude of daytime levodopa responses without requiring any change to the medication regimen. The evening protein bolus may produce some degree of wearing-off later in the day, but this is an acceptable trade-off when daytime function is the priority.

• Option A: Option A is incorrect. Eliminating all dietary protein is nutritionally unsafe and unnecessary; protein redistribution achieves the goal of protecting daytime levodopa efficacy without risking protein deficiency, and taking amino acid supplements at bedtime would still introduce LNAA competition at the evening levodopa doses without solving the daytime problem.
• Option B: Option B is incorrect. Distributing protein evenly across all meals maintains constant LNAA competition throughout the day rather than concentrating competition in the evening when it matters less; this does not address the meal-related wearing-off problem.
• Option D: Option D is incorrect. Taking all daily levodopa doses simultaneously in the morning is not a clinically feasible or appropriate strategy; levodopa's short half-life requires multiple daily doses to maintain therapeutic CNS levels throughout the day, and a single large morning dose would produce a single large peak followed by prolonged trough.
• Option E: Option E is incorrect. The intestinal gel formulation of levodopa/carbidopa bypasses gastric emptying variability and delivers continuous drug to the jejunum, but it does not bypass LNAA competition at the intestinal transporter, which operates in the small intestine; additionally, this is a device-based therapy for advanced PD, not a standard intervention for meal-related wearing-off in a patient whose morning response is reliable.

ANSWER: A

Rationale:

This question asked you to identify the agent with modest DIP symptom benefit and specify the age-related limitation. Option A is correct. Anticholinergic agents including trihexyphenidyl (an antiparkinsonian anticholinergic) and benztropine can provide modest symptomatic benefit in drug-induced parkinsonism by partially rebalancing the striatal cholinergic-dopaminergic equilibrium that is disrupted when dopaminergic tone is pharmacologically reduced. In the nigrostriatal pathway, acetylcholine and dopamine exert reciprocally antagonistic effects; reducing cholinergic activity partially compensates for dopaminergic deficiency. However, the anticholinergic adverse effects of these agents — most critically, cognitive impairment, confusion, and delirium from central muscarinic blockade — are substantially amplified in older adults with reduced cholinergic reserve, making them poorly tolerated and potentially dangerous in this population. They are more appropriate for younger patients with drug-induced parkinsonism.

• Option B: Option B is incorrect. Amantadine's NMDA receptor antagonism does not reverse D2 receptor blockade; amantadine has its own modest antiparkinson mechanism but does not displace antipsychotic agents from D2 receptors. Additionally, amantadine requires renal dose adjustment in older patients and carries its own cognitive adverse effect profile.
• Option C: Option C is incorrect. Clozapine's low D2 affinity means some receptor availability is present, but levodopa is generally not effective in the context of ongoing antipsychotic D2 blockade even with a low-affinity agent; the preferred strategy for clozapine-induced DIP (which is less common given clozapine's low D2 affinity) would be dose adjustment rather than levodopa addition.
• Option D: Option D is incorrect. Dopamine agonists including pramipexole cannot reliably overcome D2 receptor blockade by competing against an antipsychotic at clinical concentrations; higher agonist doses would also risk worsening psychosis. Additionally, pramipexole's D3 selectivity does not confer safety in older adults — renal dose adjustment is required and orthostatic hypotension risk remains.
• Option E: Option E is incorrect. Rasagiline prevents dopamine breakdown by inhibiting MAO-B, increasing synaptic dopamine availability; however, this increase in dopamine cannot act effectively at receptors that are occupied by the antipsychotic, making rasagiline ineffective as a treatment for antipsychotic-induced DIP.

ANSWER: D

Rationale:

This question asked you to identify the pharmacological property that distinguishes cinnarizine and flunarizine from other calcium channel blockers and explains their parkinsonian potential. Option D is correct. Cinnarizine and flunarizine are pharmacologically unusual calcium channel blockers in that they also possess significant dopamine D2 receptor blocking activity — a property not shared by other clinically used calcium channel blocker classes such as dihydropyridines (amlodipine, nifedipine), phenylalkylamines (verapamil), or benzothiazepines (diltiazem). This dual pharmacology means cinnarizine and flunarizine can produce parkinsonism through two independent mechanisms: pharmacological D2 receptor blockade in the striatum (the same mechanism as antipsychotic-induced DIP) and potentially through calcium channel effects on dopaminergic neuronal function. Their D2 blocking activity at therapeutic doses is sufficient to cause clinically significant parkinsonism, explaining why they are a leading cause of DIP in countries where they are prescribed, despite being used for non-psychiatric indications.

• Option A: Option A is incorrect. Selective L-type calcium channel blockade in substantia nigra neurons is a proposed mechanism that has actually been investigated as potentially neuroprotective in PD research, not as a cause of DIP; standard L-type calcium channel blockers used for hypertension and angina do not produce parkinsonism.
• Option B: Option B is incorrect. Cinnarizine and flunarizine do not inhibit VMAT2; VMAT2 inhibition is the mechanism of tetrabenazine and reserpine, a separate class of dopamine-depleting agents.
• Option C: Option C is incorrect. N-type calcium channel blockade at synaptic terminals would reduce dopamine vesicle exocytosis, but this is not the established mechanism by which cinnarizine and flunarizine cause DIP; their D2 receptor blocking activity is the pharmacologically established explanation.
• Option E: Option E is incorrect. Cinnarizine and flunarizine do not inhibit tyrosine hydroxylase; tyrosine hydroxylase inhibition is the mechanism of alpha-methyltyrosine (metyrosine), a pharmacologically distinct agent used in pheochromocytoma management, not a property of calcium channel blockers.

ANSWER: B

Rationale:

This question asked you to identify all clinically relevant anatomical sites of LNAA competition between dietary amino acids and levodopa. Option B is correct. The large neutral amino acid (LNAA) transporter — specifically the LAT1 and LAT2 isoforms — mediates levodopa transport at two distinct and clinically important anatomical sites. First, at the intestinal epithelium: levodopa is absorbed from the gut lumen into the bloodstream through LNAA transporters on enterocytes. After a high-protein meal, the gut lumen is flooded with dietary amino acids that compete with levodopa for these transporters, reducing the rate and extent of intestinal levodopa absorption. Second, at the blood-brain barrier: levodopa crosses from the systemic circulation into the CNS via LNAA transporters on the luminal surface of brain capillary endothelial cells. Elevated plasma amino acid concentrations from protein digestion compete with levodopa for these transporters, reducing CNS levodopa delivery. Both sites contribute to the clinical phenomenon of post-meal levodopa wearing-off, and the protein redistribution diet addresses both by reducing the dietary amino acid load competing at each site.

• Option A: Option A is incorrect. Competition occurs at both the intestinal epithelium and the blood-brain barrier; attributing the interaction exclusively to the blood-brain barrier omits the intestinal absorption component, which is well established and clinically significant.
• Option C: Option C is incorrect. Competition occurs at both sites; attributing it exclusively to the intestinal epithelium omits the blood-brain barrier component, which is equally well established and accounts for additional CNS delivery reduction even when plasma levodopa levels appear adequate.
• Option D: Option D is incorrect. Renal tubular LNAA transporters do not play a clinically recognized role in the dietary protein-levodopa interaction; renal handling of levodopa is not the mechanism of meal-related wearing-off.
• Option E: Option E is incorrect. Hepatic sinusoidal LNAA competition with dietary amino acids is not an established mechanism for levodopa bioavailability reduction; levodopa hepatic extraction is primarily through AADC and COMT enzymatic pathways, not through competitive transporter kinetics at the hepatocyte membrane.

ANSWER: E

Rationale:

This question asked you to precisely characterize pimavanserin's mechanism and explain its suitability for PD psychosis. Option E is correct. Pimavanserin is a selective inverse agonist at serotonin 5-HT2A receptors — and to a lesser extent 5-HT2C receptors — with no meaningful affinity for dopamine receptors, histamine receptors, or muscarinic receptors at clinical doses. Because it exerts its antipsychotic effect entirely through serotonergic rather than dopaminergic mechanisms, pimavanserin does not block striatal D2 receptors and therefore does not worsen the motor features of Parkinson's disease. This makes it uniquely suitable for the management of PD-associated psychosis, a condition where most conventional antipsychotics — which achieve their efficacy through D2 blockade — are contraindicated or poorly tolerated. Pimavanserin received FDA approval specifically for hallucinations and delusions associated with Parkinson's disease psychosis. It is also an option for postoperative delirium management in PD patients where D2-blocking agents must be avoided.

• Option A: Option A is incorrect. Pimavanserin does not act at D3 receptors; it has no significant dopamine receptor activity, which is precisely the pharmacological property that makes it suitable for PD. D3 partial agonism is not the basis for its antipsychotic mechanism.
• Option B: Option B is incorrect. Pimavanserin is not a serotonin-dopamine activity modulator and does not partially block D2 receptors; serotonin-dopamine activity modulators are a distinct class that includes agents like lumateperone, not pimavanserin, which is distinguished by its complete absence of D2 receptor activity.
• Option C: Option C is incorrect. Pimavanserin does not act at glutamate NMDA receptors; NMDA receptor antagonism is the mechanism of memantine and of ketamine, not of pimavanserin.
• Option D: Option D is incorrect. Pimavanserin does not act at muscarinic M1 receptors; it has no significant muscarinic receptor affinity, and M1 antagonism is not the basis for its antipsychotic properties or its suitability in PD.